Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04849273 · ClinicalTrials.gov registry record · Phase 1
A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
A Phase 1 study, sponsored by Turning Point Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT04849273 is a Phase 1 study that was terminated before completion, run by Turning Point Therapeutics. The registered enrollment target is 11 participants.
The verdict
NCT04849273, a Phase 1 study, was terminated before completion, sponsored by Turning Point Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
A phase 1, first-in-human, open-label study to evaluate the safety, tolerability, PK, and efficacy of the novel ALK inhibitor TPX-0131 in pretreated subjects with ALK+ advanced or metastatic non-small cell lung cancer (NSCLC).
Interventions
- DRUG TPX-0131
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2023-04-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04849273
The ClinicalTrials.gov registry entry for NCT04849273 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Turning Point Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TPX-0131 is the first listed.
NCT04849273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04849273 about?
NCT04849273 is a clinical study titled "A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC". A phase 1, first-in-human, open-label study to evaluate the safety, tolerability, PK, and efficacy of the novel ALK inhibitor TPX-0131 in pretreated subjects with ALK+ advanced or metastatic non-small cell lung cancer (NSCLC).
What is the current status of trial NCT04849273?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2021-07-28. Estimated completion is 2023-04-18.
What interventions are being tested in trial NCT04849273?
The interventions under investigation include: TPX-0131 (DRUG).
Who is sponsoring clinical trial NCT04849273?
This trial is sponsored by Turning Point Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.